目的 探讨更昔洛韦（ganciclovir,GCV）治疗小儿传染性单核细胞增多症（infectious mononucleosis,IM）的临床疗效并分析其对EB病毒（epstein-barr virus）特异性抗体（VCA-IgM）的影响.方法 选取2011年1月至2014年1月成都青白江区人民...目的 探讨更昔洛韦（ganciclovir,GCV）治疗小儿传染性单核细胞增多症（infectious mononucleosis,IM）的临床疗效并分析其对EB病毒（epstein-barr virus）特异性抗体（VCA-IgM）的影响.方法 选取2011年1月至2014年1月成都青白江区人民医院儿科收治的IM患儿60例,随机将其分至观察组和对照组.观察组给予GCV治疗,对照组给予干扰素（IFN-α）治疗.比较两组患儿临床症状改善情况、治疗有效率、治疗后VCA-IgM抗体转阴以及不良反应等情况.结果 观察组退热时间以及咽峡炎症状好转时间明显短于对照组[（3.57±1.24）d vs （4.76±1.35）d]、[（4.73±1.36）d vs （6.22±1.75）d]（P＜0.05）,治疗显效率明显大于对照组（50.0％ vs 26.7％,P＜0.05）,治疗后3个月的VCA-IgM抗体阳性率明显小于对照组（13.3％ vs 53.3％,P＜0.05）,无明显不良反应发生.结论 GCV在小儿IM的治疗中疗效显著,可促使EBv特异性抗体转阴.展开更多
目的探讨干扰素联合更昔洛韦治疗带状疱疹的临床疗效及对后遗神经痛和IL-6、IL-10的影响。方法选取2014年1月~2015年2月于黑龙江省电力医院治疗的106例带状疱疹患者作为研究对象,随机数字表法分为对照组52例和观察组54例。2组患者均给...目的探讨干扰素联合更昔洛韦治疗带状疱疹的临床疗效及对后遗神经痛和IL-6、IL-10的影响。方法选取2014年1月~2015年2月于黑龙江省电力医院治疗的106例带状疱疹患者作为研究对象,随机数字表法分为对照组52例和观察组54例。2组患者均给予止痛等对症治疗。在此基础上,对照组给予更昔洛韦治疗,观察组在对照组基础上联合应用干扰素治疗。观察比较组间带状疱疹临床疗效、后遗神经痛发生率、后遗神经痛患者疼痛评分及炎性因子IL-6、IL-10水平,并于治疗期间观察不良反应发生情况。结果观察组带状疱疹治疗总有效率显著高于对照组（92.6%vs 78.8%,P〈0.05）。治疗后,观察组和对照组后遗神经痛发生率分别为44.4%和50.0%,组间比较差异无统计学意义,而观察组后遗神经痛患者VAS评分低于对照组[（3.5±0.7）分vs（5.8±0.9）分,P〈0.05]。炎性因子方面,与对照相比,观察组治疗后IL-6水平降低[（137.6±32.4）pg/m L vs（340.5±30.6）pg/m L,P〈0.05],IL-10水平升高[（179.3±22.5）μg/m L vs（150.6±24.1）μg/m L,P〈0.05]。治疗期间,2组患者均无严重不良反应。结论干扰素联合更昔洛韦治疗带状疱疹能够显著提高临床疗效,减轻后遗神经痛疼痛程度,且不良反应轻微。展开更多
The link between cytomegalovirus(CMV) infection and inflammatory bowel diseases remains an important subject of debate. CMV infection is frequent in ulcerative colitis(UC) and has been shown to be potentially harmful....The link between cytomegalovirus(CMV) infection and inflammatory bowel diseases remains an important subject of debate. CMV infection is frequent in ulcerative colitis(UC) and has been shown to be potentially harmful. CMV reactivation needs to be diagnosed using methods that include in situ detection of viral markers by immunohistochemistry or by nucleic acid amplification techniques. Determination of the density of infection using quantitative tools(numbers of infected cells or copies of the genome) is particularly important. Although CMV reactivation can be considered as an innocent bystander in active flareups of refractory UC, an increasing number of studies suggest a deleterious role of CMV in this situation. The presence of colonic CMV infection is possibly linked to a decreased response to steroids and other immunosuppressive agents. Some treatments, notably steroids and cyclosporine A, have been shown to favor CMV reactivation, which seems not to be the case for therapies using anti-tumor necrosis factor drugs. According to these findings, in flare-ups of refractory UC, it is now recommended to look for the presence of CMV reactivation by using quantitative tools in colonic biopsies and to treat them with ganciclovir in cases of high viral load or severe disease.展开更多
文摘目的 探讨更昔洛韦（ganciclovir,GCV）治疗小儿传染性单核细胞增多症（infectious mononucleosis,IM）的临床疗效并分析其对EB病毒（epstein-barr virus）特异性抗体（VCA-IgM）的影响.方法 选取2011年1月至2014年1月成都青白江区人民医院儿科收治的IM患儿60例,随机将其分至观察组和对照组.观察组给予GCV治疗,对照组给予干扰素（IFN-α）治疗.比较两组患儿临床症状改善情况、治疗有效率、治疗后VCA-IgM抗体转阴以及不良反应等情况.结果 观察组退热时间以及咽峡炎症状好转时间明显短于对照组[（3.57±1.24）d vs （4.76±1.35）d]、[（4.73±1.36）d vs （6.22±1.75）d]（P＜0.05）,治疗显效率明显大于对照组（50.0％ vs 26.7％,P＜0.05）,治疗后3个月的VCA-IgM抗体阳性率明显小于对照组（13.3％ vs 53.3％,P＜0.05）,无明显不良反应发生.结论 GCV在小儿IM的治疗中疗效显著,可促使EBv特异性抗体转阴.
文摘目的探讨干扰素联合更昔洛韦治疗带状疱疹的临床疗效及对后遗神经痛和IL-6、IL-10的影响。方法选取2014年1月~2015年2月于黑龙江省电力医院治疗的106例带状疱疹患者作为研究对象,随机数字表法分为对照组52例和观察组54例。2组患者均给予止痛等对症治疗。在此基础上,对照组给予更昔洛韦治疗,观察组在对照组基础上联合应用干扰素治疗。观察比较组间带状疱疹临床疗效、后遗神经痛发生率、后遗神经痛患者疼痛评分及炎性因子IL-6、IL-10水平,并于治疗期间观察不良反应发生情况。结果观察组带状疱疹治疗总有效率显著高于对照组（92.6%vs 78.8%,P〈0.05）。治疗后,观察组和对照组后遗神经痛发生率分别为44.4%和50.0%,组间比较差异无统计学意义,而观察组后遗神经痛患者VAS评分低于对照组[（3.5±0.7）分vs（5.8±0.9）分,P〈0.05]。炎性因子方面,与对照相比,观察组治疗后IL-6水平降低[（137.6±32.4）pg/m L vs（340.5±30.6）pg/m L,P〈0.05],IL-10水平升高[（179.3±22.5）μg/m L vs（150.6±24.1）μg/m L,P〈0.05]。治疗期间,2组患者均无严重不良反应。结论干扰素联合更昔洛韦治疗带状疱疹能够显著提高临床疗效,减轻后遗神经痛疼痛程度,且不良反应轻微。
文摘The link between cytomegalovirus(CMV) infection and inflammatory bowel diseases remains an important subject of debate. CMV infection is frequent in ulcerative colitis(UC) and has been shown to be potentially harmful. CMV reactivation needs to be diagnosed using methods that include in situ detection of viral markers by immunohistochemistry or by nucleic acid amplification techniques. Determination of the density of infection using quantitative tools(numbers of infected cells or copies of the genome) is particularly important. Although CMV reactivation can be considered as an innocent bystander in active flareups of refractory UC, an increasing number of studies suggest a deleterious role of CMV in this situation. The presence of colonic CMV infection is possibly linked to a decreased response to steroids and other immunosuppressive agents. Some treatments, notably steroids and cyclosporine A, have been shown to favor CMV reactivation, which seems not to be the case for therapies using anti-tumor necrosis factor drugs. According to these findings, in flare-ups of refractory UC, it is now recommended to look for the presence of CMV reactivation by using quantitative tools in colonic biopsies and to treat them with ganciclovir in cases of high viral load or severe disease.
